Skip to main content
. Author manuscript; available in PMC: 2023 Dec 13.
Published in final edited form as: J Am Coll Cardiol. 2022 Nov 2;80(24):e223–e393. doi: 10.1016/j.jacc.2022.08.004

Recommendations for Medical Therapy in Marfan Syndrome

Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR LOE RECOMMENDATIONS
1 A 1. In patients with Marfan syndrome, treatment with either a beta blocker or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce the rate of aortic dilation.1,2
2a C-LD 2. In patients with Marfan syndrome, the use of both a beta blocker and an ARB, in maximally tolerated doses (unless contraindicated), is reasonable to reduce the rate of aortic dilation.3,4